These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 9135852)

  • 1. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
    Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
    Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
    Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
    Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion.
    Lai RS; Chen CC; Lee PC; Lu JY
    Jpn J Clin Oncol; 1999 Sep; 29(9):421-4. PubMed ID: 10563194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer.
    Stieber P; Dienemann H; Hasholzner U; Müller C; Poley S; Hofmann K; Fateh-Moghadam A
    Eur J Clin Chem Clin Biochem; 1993 Oct; 31(10):689-94. PubMed ID: 7507359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer.
    Bates J; Rutherford R; Divilly M; Finn J; Grimes H; O'Muircheartaigh I; Gilmartin JJ
    Eur Respir J; 1997 Nov; 10(11):2535-8. PubMed ID: 9426091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
    Seemann MD; Beinert T; Fürst H; Fink U
    Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
    Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
    Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
    Ebert W; Hoppe M; Muley T; Drings P
    Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.
    van der Gaast A; Schoenmakers CH; Kok TC; Blijenberg BG; Cornillie F; Splinter TA
    Br J Cancer; 1994 Mar; 69(3):525-8. PubMed ID: 7510117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and cytokeratin 19 fragment levels.
    Kashiwabara K; Nakamura H; Esaki T
    Clin Chim Acta; 2000 Apr; 294(1-2):105-13. PubMed ID: 10727677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis.
    Pastor A; Menéndez R; Cremades MJ; Pastor V; Llopis R; Aznar J
    Eur Respir J; 1997 Mar; 10(3):603-9. PubMed ID: 9072992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYFRA 21-1 as a tumour marker for bronchogenic carcinoma.
    Rapellino M; Niklinski J; Pecchio F; Furman M; Baldi S; Chyczewski L; Ruffini E; Chyczewska E
    Eur Respir J; 1995 Mar; 8(3):407-10. PubMed ID: 7540561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer.
    Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO
    J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS.
    Mady EA
    Int J Biol Markers; 2001; 16(2):130-5. PubMed ID: 11471896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Cyfra 21-1 as a marker for lung cancer.
    Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
    Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor markers kinetic in malignant lung neoplasms.
    Cristofori R; Aimo G; Mengozzi G; Oliaro A; Revello F; Rapellino M
    J Cardiovasc Surg (Torino); 1999 Apr; 40(2):299-305. PubMed ID: 10350122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
    Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V
    Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?
    Plebani M; Basso D; Navaglia F; De Paoli M; Tommasini A; Cipriani A
    Br J Cancer; 1995 Jul; 72(1):170-3. PubMed ID: 7541234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.